Crystalline Benzamide Salt Forms for T-Type Calcium Channel Diseases
Summary
USPTO published patent application US20260092037A1 disclosing crystalline salt forms of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide useful for treating T-type calcium channel diseases including epilepsy, essential tremor, and major depressive disorder. The application (No. 19311876) was filed August 27, 2025, naming inventors David T. Jonaitis and Lisa McCracken.
What changed
USPTO published patent application US20260092037A1 disclosing crystalline and salt forms of a benzamide compound (N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide) useful for preventing and treating diseases relating to aberrant T-type calcium channel function, including epilepsy syndromes (absence seizures, juvenile myoclonic epilepsy, genetic epilepsy), essential tremor, and psychiatric disorders such as major depressive disorder. The application names David T. Jonaitis and Lisa McCracken as inventors and was filed August 27, 2025 under Application No. 19311876.
Pharmaceutical companies and drug manufacturers should review the compound claims to assess freedom-to-operate for T-type calcium channel targeted therapies. Investors in pharmaceutical or biotechnology companies should consider this intellectual property portfolio development. Patent protection, if granted, would provide exclusivity through the patent term.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CRYSTALLINE SALT FORMS OF N-((1-(2-(TERT-BUTYLAMINO)-2-OXOETHYL)PIPERIDIN-4-YL) METHYL)-3-CHLORO-5-FLUOROBENZAMIDE AND METHODS OF USE THEREOF
Application US20260092037A1 Kind: A1 Apr 02, 2026
Inventors
David T. Jonaitis, Lisa McCracken
Abstract
Described herein, in part, are crystalline and salt forms of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)).
CPC Classifications
C07D 211/26 A61K 31/445 C07C 55/07 C07C 55/08 C07C 55/12 C07C 55/14 C07C 55/20 C07C 57/145 C07C 57/15 C07C 65/11 C07C 307/02 C07C 309/04 C07C 309/05 C07C 309/29 C07C 309/35 C07D 239/557 C07B 2200/13
Filing Date
2025-08-27
Application No.
19311876
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.